JAPAN

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD80 billion as at 31 December 2017.

Source: December 2017 IMS

STATISTICS

Number of products launched:

9

(2017: 9)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USDnil

3 – 5 years

USDnil

Number of product recalls:

Nil

(2017: nil)

Average staff turnover:

20,0%

(2017: 20,7%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	1 930	1 812	7
Regional Brands	297	172	73
Anaesthetics	1 213	1 204	1
Thrombosis	48	57	(16)
High Potency & Cytotoxics	372	379	(2)